Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity

Cancer cells may use PARP enzymes and Homologous Recombination to repair single and double strand breaks caused by genotoxic insults. In this study, the PARP‐1 inhibitor Rucaparib was utilized to increase the sensitivity to chemoradiotherapy treatment in BRCA‐2‐deficient and ‐proficient pancreatic c...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Oncol
Päätekijät: Porcelli, Letizia, Quatrale, Anna E., Mantuano, Paola, Leo, Maria G., Silvestris, Nicola, Rolland, Jean F., Carioggia, Enza, Lioce, Marco, Paradiso, Angelo, Azzariti, Amalia
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2012
Aiheet:
Papers
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528465/
https://ncbi.nlm.nih.gov/pubmed/23148997
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2012.10.002
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia